A rare case of eptifibatide-induced thrombocytopenia [PDF]
Journal of Community Hospital Internal Medicine Perspectives, 2021 Eptifibatide is a glycoprotein (GP) IIb/IIIa receptor antagonist, used for the treatment of acute coronary syndrome with high-risk features or ongoing ischemia.
Khalil Kamar +4 more
doaj +5 more sources
Eptifibatide bolus dose postductal stenting intervention: A single-center experience [PDF]
Annals of Pediatric CardiologyObjectives: Stent thrombosis, a potential complication of ductal stenting, is associated with high mortality. This is a catastrophic complication, which can occur acutely (within 24 h), subacutely (within 30 days), or late (≥30 days) after stent ...
Rishika Mehta +5 more
doaj +3 more sources
The Egyptian Heart Journal, 2023 Background ST-segment elevation myocardial infarction (STEMI) is usually caused by a rupture in the atherosclerotic plaque, followed by platelet aggregation which ultimately leads to acute coronary artery occlusion.
Rozita Jalalian +5 more
doaj +2 more sources
Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage
Case Reports in Critical Care, 2021 Background. Eptifibatide is a glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitor which prevents platelet activation. The mechanism in which eptifibatide causes profound thrombocytopenia is poorly understood. One hypothesis suggests antibody-dependent
Gregory Byrd +5 more
doaj +2 more sources
Eptifibatide provides additional platelet inhibition in Non–ST-Elevation myocardial infarction patients already treated with aspirin and clopidogrel Results of the platelet activity extinction in Non–Q-Wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study [PDF]
, 2004 ObjectivesThe present study hypothesis was that eptifibatide offered further antiplatelet efficacy above clopidogrel in non–ST-elevation myocardial infarction (NSTEMI) patients before an expeditive coronary intervention.BackgroundAlthough thienopyridines
Choussat, Rémi +10 more
core +2 more sources
In vitro and patient studies with platelets to explore off-target cardiovascular effects of integrase inhibitors. [PDF]
HIV MedAbstract Introduction People with HIV currently face a tenfold higher risk of developing cardiovascular disease (CVD) than those without HIV. Studies have shown various off‐target effects of antiretroviral treatment (ART) on the cardiovascular system, but little is known about the effects of currently used integrase strand transfer inhibitors (INSTIs ...
Keniyopoullos R +3 more
europepmc +2 more sources
Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism(s) [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023 Thrombocytopenia is a rare but serious complication of the intravenous glycoprotein IIb/IIIa (GPIIb/IIIa; integrin αIIbβ3) receptor inhibitors (GPIs), abciximab, eptifibatide, and tirofiban. The thrombocytopenia ranges from mild (50 000–100 000 platelets/
Sem A. O. F. Rikken +4 more
doaj +2 more sources
Interdisciplinary Neurosurgery, 2021 Background: Glycoprotein IIb/IIIa inhibitor use in acute ischemic stroke (AIS) during mechanical thrombectomy (MT) and acute stenting and angioplasty is a topic consistently debated due to concerns over safety and efficacy.
Hari Movva +6 more
doaj +2 more sources
Eptifibatide-induced profound thrombocytopaenia: a rare complication
BMJ Case Reports, 2021 Drug-induced immune thrombocytopaenia (DITP) is a type of thrombocytopaenia caused by medications. It is one of the common causes of unexplained thrombocytopaenia.
Pranav Mahajan +3 more
semanticscholar +4 more sources